Parkinson's disease involves monocytic alterations in the blood. The cells have reduced viability and are unresponsive to specific stimuli, which could have relevant consequences for the progression of Parkinson's. Immune modulation medications may be a new treatment option to inhibit neurodegeneration associated with PD.